ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Nov 18, 2021 15:28 JST
Source:
Eisai
Eisai Receives the 'Most Liked!' IR Award at The 2021 IR Award
TOKYO, Nov 18, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that it has been selected as the winner of the "Most Liked!" IR Award at the 2021 IR Award, hosted by the Japan Investor Relations Association.
The "Most Liked!" IR Award has been newly created for commemorating the 25th anniversary of the Best IR Award in 2020. The award is designed to reflect the viewpoints of companies that applied for the IR Award based on their voting, share their proactive IR experiences, and realize best practices. The theme for 2021 is "IR activities contributing sustainability," awarding companies that have actively promoted information disclosure and their dialogue with investors on sustainability-related matters. Of the companies that applied for the 2021 IR Award, 178 companies entered the 'Most Liked!" IR Award and the top 17 companies, including Eisai, were selected based on a mutual vote by the candidate companies.
For further details, please visit the JIRA website:
https://www.jira.or.jp/english/
.
Eisai has focused on disseminating information regarding financial capital and non-financial capital value relevance that link to corporate value for longer-term as well as continuously through publicizing the results of the analysis of the correlation between ESG-related indicators and PBR (Price Book-value Ratio) , holding discussion meetings with investors, or publishing the Eisai Value Creation Report. The award was given to Eisai with "empathy" for Eisai's efforts to visualize ESG.
Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Together with strengthening its ESG initiatives in order to realize this corporate philosophy, Eisai respects the rights of shareholders and investors, ensures fairness and transparency in management, and works on its IR activities to aid the enhancement of corporate value.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: Healthcare & Pharm
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
EASD 2025 | HighTide Therapeutics Announces Oral Presentation of Phase 3 Data in Patients with Type 2 Diabetes
Sep 19, 2025 09:00 JST
Mitsubishi Motors Launches the All-New Eclipse Cross Electric Vehicle for the European Market
Sep 19, 2025 00:58 JST
Mitsubishi Motors to Begin Sales of All-New Delica Mini and eK Space in Japan in October
Sep 19, 2025 00:50 JST
Upgraded GR Corolla Set for Japan Launch
Sep 19, 2025 00:48 JST
Honda Koraidon Ride on Experience and Onboard Showrun to be Held at Honda Collection Hall
Sep 19, 2025 00:42 JST
Mitsubishi Motors Increases Investment Stake in Australian Automotive Financial Services Company to 19.93%
Sep 19, 2025 00:27 JST
MHI Is Awarded Contract for 20 Units of the Outer Vertical Target for the Divertor Used in the ITER in Southern France
Sep 19, 2025 00:16 JST
NTT and Mitsubishi Heavy Industries Achieved World's Highest Efficiency in Laser Wireless Power Transmission under Atmospheric Turbulence
Sep 19, 2025 00:00 JST
Definitive agreement to implement a joint mine plan between Los Bronces and Andina copper mines
Sep 17, 2025 18:57 JST
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
Sep 17, 2025 18:20 JST
Honda Announces New Electric Motorcycle "Honda WN7" in Europe
Sep 17, 2025 17:46 JST
Honda Develops New "Chemical Sorting" Technology to Separate Solid Contaminants from Waste Plastics Derived from End-of-life Automobiles
Sep 16, 2025 15:00 JST
NEC Publishes ESG Initiatives Supporting Sustainable Growth of Companies and Society in "ESG Databook 2025"
Sep 16, 2025 14:00 JST
JSR Corporation/Inpria Corporation and Lam Research Enter Cross Licensing and Collaboration Agreement to Advance Semiconductor Manufacturing
Sep 16, 2025 09:00 JST
Toyota Launches Next-Generation New Mobility e-Palette
Sep 15, 2025 15:33 JST
The University of Osaka D3 Center Commences Operation of New Computing and Data Infrastructure Built by NEC
Sep 12, 2025 15:08 JST
GR Yaris "Aero performance package" Set for Japan Launch
Sep 12, 2025 14:40 JST
Mitsubishi Heavy Industries Achieves Target Performance at Pilot Plant for Bioethanol Membrane Dehydration Systems
Sep 12, 2025 14:19 JST
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
Sep 12, 2025 13:20 JST
TANAKA PRECIOUS METAL TECHNOLOGIES Succeeds in Developing High-Performance Palladium Alloy Hydrogen Permeable Membrane Operable in the Low-Temperature Range of 300 degrees C
Sep 12, 2025 11:00 JST
More Latest Release >>
Related Release
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
9/17/2025 6:20:00 PM JST
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
9/12/2025 1:20:00 PM JST
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
9/8/2025 5:49:00 PM JST
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
9/4/2025 10:56:00 AM JST
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
9/3/2025 11:32:00 AM JST
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
9/1/2025 1:44:00 PM JST
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
8/29/2025 6:17:00 PM JST
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
8/25/2025 7:30:00 PM JST
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
8/18/2025 9:11:00 AM JST
Revenue of LEQEMBI(R) (Preliminary Basis)
7/31/2025 6:27:00 PM JST
More Press release >>